文献速递心境障碍

重度抑郁症治疗中断随机安慰剂对照试验中复发轨迹的个体患者数据荟萃分析

Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis.
PubMed 文献 · Lancet Psychiatry · 2017-02-09

该研究分析四项双盲停药试验的个体患者数据(n=1462),使用生长混合模型识别抑郁严重度轨迹。结果显示活性药物与安慰剂组存在相似的复发轨迹,持续治疗仅提供约13%的保护效应(33% vs 46%),提示无特异性停药复发特征。

要点

  • 活性药物与安慰剂组复发轨迹相似,无特异性停药复发特征。
  • 持续抗抑郁治疗对复发的保护效应约13%(33% vs 46%)。
  • 女性、临床应答时间短、基线CGI高增加复发轨迹归属几率。

核心结论

  • 活性药物与安慰剂组存在相似的复发轨迹,提示无特异性停药相关复发特征。
  • 持续治疗对复发仅有适度保护作用,需将预防复发策略纳入抑郁症治疗。

研究设计与样本

  • 分析四项2012年前双盲停药临床试验的个体患者数据,涉及度洛西汀或氟西汀与安慰剂对照,n=1462。
  • 使用生长混合模型建模双盲治疗至26周的复发轨迹,并以加权逻辑回归评估轨迹类别预测因素。

主要发现

  • 在活性药物和安慰剂组均识别出相似的复发轨迹及两个稳定正常范围抑郁评分轨迹。
  • 抗抑郁药相对安慰剂对复发分类风险的总体保护效应约13%(33% vs 46%)。

关键数值与推荐

  • 复发率:活性药物组33% vs 安慰剂组46%,保护效应约13%。

临床怎么用

  • 持续抗抑郁治疗对预防复发的保护效应有限,需结合其他预防复发策略。
  • 女性、临床应答时间短、基线CGI高的患者可能需更密切监测复发风险。

局限性

  • 仅分析四项2012年前度洛西汀或氟西汀停药试验的个体数据,外推需谨慎。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Understanding patterns of relapse in patients who respond to antidepressant treatment can inform strategies for prevention of relapse. We aimed to identify distinct trajectories of depression severity, assess whether similar or different trajectory classes exist for patients who continued or discontinued active treatment, and test whether clinical predictors of trajectory class membership exist using pooled data from clinical trials. METHODS: We analysed individual patient data from four double-blind discontinuation clinical trials of duloxetine or fluoxetine versus placebo in major depression from before 2012 (n=1462). We modelled trajectories of relapse up to 26 weeks during double-blind treatment. Trajectories of depression severity, as measured by the Hamilton Depression Rating Scale score, were identified in the entire sample, and separately in groups in which antidepressants had been continued or discontinued, using growth mixture models. Predictors of trajectory class membership were assessed with weighted logistic regression. FINDINGS: We identified similar relapse trajectories and two trajectories of stable depression scores in the normal range on active medication and on placebo. Active treatment significantly lowered the odds of membership in the relapse trajectory (odds ratio 0·47, 95% CI 0·37-0·61), whereas female sex (1·56, 1·23-2·06), shorter length of time with clinical response by 1 week (1·10, 1·06-1·15), and higher Clinical Global Impression score at baseline (1·28, 1·01-1·62) increased the odds. Overall, the protective effect of antidepressant medication relative to placebo on the risk of being classified as a relapser was about 13% (33% vs 46%). INTERPRETATION: The existence of similar relapse trajectories on active medication and on placebo suggests that there is no specific relapse signature associated with antidepressant discontinuation. Furthermore, continued treatment offers only modest protection against relapse. These data highlight the need to incorporate treatment strategies that prevent relapse as part of the treatment of depression. FUNDING: National Institutes of Health, the US Department of Veterans Affairs Alcohol Research Center, and National Center for Post-Traumatic Stress Disorder.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Gueorguieva R, Chekroud AM, Krystal JH, et al. Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis. Lancet Psychiatry. 2017. PMID: 28189575. doi:10.1016/S2215-0366(17)30038-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。